Introduction
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide and is estimated to afflict approximately 20% of the general population in developed countries [1, 2] . NAFLD can be divided into simple steatosis (SS) and nonalcoholic steatohepatitis (NASH) by histological findings.
NASH is characterized by the presence of ballooning and lobular inflammation in addition to macrovesicular steatosis [3, 4] and may progress to cirrhosis, hepatocellular carcinoma, and ultimately death [4, 5] . Lipotoxicity, oxidative stress, pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-, bacterial lipopolysaccarides, and iron accumulation in the liver are presumed to trigger the progression of steatosis to steatohepatitis [1, 6] .
The hallmark feature of NAFLD/NASH is accumulation of triglycerides (TG) in the liver. Sources of intrahepatic TG include non-esterified fatty acids (FAs) released from adipose tissue and taken up from the blood, as well as those newly synthesized from citrate. FAs are later metabolized mainly by -oxidation or by esterification to produce TG, which are either stored in hepatocytes or incorporated into very-low-density lipoprotein (VLDL) particles for export. An imbalance among these metabolic pathways may lead to hepatic steatosis [1, 6] .
In 1990, Powell et al. first reported a NASH patient who progressed to cirrhosis without hepatic fat deposition in 5 years [7] . Other reports have also demonstrated a significant reduction in hepatic TG accumulation in patients with advanced NASH, which is also designated as burned-out NASH [5, 8] . This phenomenon implicates altered hepatic FA/TG metabolism with progression of NAFLD, but its precise molecular mechanism remains unclear. To clarify this, we assessed the hepatic expression of key genes involved in FA/TG metabolism in patients having SS, NASH with mild fibrosis, and NASH with severe fibrosis. 5 
Patients and Methods

Patients
Fifty NAFLD patients who underwent a liver biopsy at Shinshu University or its and (4) the absence of other types of chronic liver disease, such as autoimmune liver disease, hereditary hemochromatosis, Wilson's disease, 1-antitrypsin deficiency, and citrin deficiency [10] . The diagnosis of NAFLD was confirmed by liver histology.
The presence of obesity was defined as having a body mass index (BMI) of more than 25 kg/m 2 based on criteria released by the Japan Society for the Study of Obesity. Patients were considered to be hypertensive if their systolic/diastolic pressure was greater than 140/90 mmHg. Patients were considered to be diabetic if they had a fasting glucose level equal to or higher than 126 mg/dL. Patients were considered to have hyperlipidemia if their fasting serum levels of cholesterol or TG were equal to or higher than 220 or 150 mg/dL, respectively [11] .
Selection of Normal Controls
Normal livers were obtained from healthy liver transplantation donors (n = 6) at the time of pre-operative percutaneous US-guided liver biopsy who satisfied the 6 following criteria: (1) the absence of past history of liver disease and regular intake of alcohol and drugs; (2) the absence of obesity, diabetes, hypertension, and hyperlipidemia; (3) normal liver function tests; and (4) normal liver histology.
Laboratory Examination
Blood samples were obtained at the time of liver biopsy following overnight fasting for 8-10 hours. Laboratory data, such as aspartate and alanine aminotransferase (AST and ALT, respectively) and -glutamyltransferase (GT),
were measured by standard methods using automated analyzers. The homeostasis model assessment for insulin resistance (HOMA-IR) value was calculated as fasting glucose (mg/dL) x immunoreactive insulin (U/mL) / 405.
Histological and Immunohistochemical Analyses
Percutaneous US-guided liver biopsies were performed as described previously [12] . The average length of the samples was 17.6 + 2.8 mm, and the average number of portal tracts found in each sample was 11.8 + 3.5. Kleiner et al [13] . The NAFLD histological activity score (NAS) was calculated as the unweighted sum of the scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2). The histological diagnosis of steatohepatitis was made by 7 the presence of macrovesicular steatosis, hepatocyte ballooning, and lobular inflammation [3, 4, 13] . Patients with macrovesicular steatosis alone were diagnosed as having SS.
Immunohistochemical staining of sterol regulatory element-binding protein (SREBP)-1c was carried out as described elsewhere [14] . The antibody used in this study (sc-367, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) can recognize two SREBP-1 isoforms, SREBP-1c and SREBP-1a. Since the expression of SREBP-1c is predominant in human livers [15, 16] , the results of 
Analysis of mRNA Expression
Total RNA was extracted using an RNeasy Mini Kit (QIAGEN, Hilden, Germany) and cDNA was prepared with a Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany). Quantitative polymerase chain reaction (qPCR) was performed using a SYBR Green PCR kit and ABI PRISM 7000 Sequence Detection System (Applied Biosystems, CA, USA). The primer sequences are shown in supplementary Table 1 , whose specificity has been confirmed by nucleotide blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). All mRNA levels were determined using the ΔΔCt method as described previously [17] . The mRNA 8 levels of target genes were normalized to those of 18S ribosomal RNA and expressed as fold changes relative to those of normal livers.
Immunoblot Analysis
Preparation of whole liver lysates was carried out as described previously [18] .
Protein concentration was measured colorimetrically with a BCA TM Protein
Assay kit (Pierce, Rockford, IL, USA). Whole liver lysates (100 g of protein)
were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis [19] . Three samples from each group were loaded into each electrophoresis assay and all samples were examined. After electrophoresis, The positions of precursor and mature SREBP-1c bands were determined by molecular weight (125 and 68 kDa, respectively). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the loading control. Band intensities were measured densitometrically, normalized to those of GAPDH, and subsequently expressed as fold changes relative to those of normal livers.
Ethics
This study was carried out in accordance with the World Medical Association
Helsinki Declaration and was approved by each hospital's respective human ethics committee. Informed consent was obtained from all patients. 
Statistical Analysis
Statistical analyses were performed using SPSS software version 11.0 for 
Clinical and Histological Findings
The clinical and histological findings of 56 participants are summarized in Table 1 and 2, respectively. In 50 NAFLD patients, BMI, serum levels of AST, ALT, and GT, and HOMA-IR values were significantly greater in the advanced NASH group than in the other groups and increased with disease progression (r = 0.332, P = 0.017 for BMI; r = 0.664, P < 0.001 for serum AST; r = 0.398, P = 0.002 for serum ALT; r = 0.480, P < 0.001 for serum GT; and r = 0.509, P < 0.001 for HOMA-IR), but platelet count and serum albumin concentrations were inversely correlated with fibrosis stage (r = -0.502, P < 0.001 and r = -0.421, P = 0.008, respectively). Lobular inflammation and ballooning scores were both positively correlated with fibrosis stage (r = 0.495 and 0.559, respectively, both P < 0.001). The degree of steatosis was the greatest in the mild NASH group, which was significantly different from that in the advanced NASH group (P = 0.008) ( Table 2 , Fig. 1 ). Steatosis scores also demonstrated a significant inverse correlation with fibrosis stage (r = -0.380, P = 0.010). These results indicate that steatosis decreased with fibrosis progression in our cohort, which is consistent with previous reports [5, 8] .
Hepatic Expression of Genes Associated with FA Oxidation and VLDL Synthesis/Export
The mRNA levels of genes encoding FA-metabolizing enzymes were measured next, but revealed no differences in the expression of mitochondrial -oxidation Fig. 2A) . Similarly, there were no significant differences in the mRNA levels of microsomal TG transfer protein (MTP) or apolipoprotein (apo) B (Fig.   2B ). Based on these results, enhancement of FA oxidation and VLDL synthesis/export is not likely to be responsible for attenuation of hepatic steatosis in advanced NASH.
Hepatic Expression of Genes Associated with FA Uptake from the Blood
The expression of FA translocase (FAT), FA-binding protein (FABP) 1, and FABP4 was examined, but no significant differences in the mRNA levels of these FA transporters were found (Fig. 2C) .
Decreased Hepatic Expression of Genes Associated with De Novo
Lipogenesis in Advanced NASH
We next assessed the expression of genes that were associated with de novo FA/TG synthesis. The mRNA levels of FA synthase (FAS) were significantly lower in the mild NASH and advanced NASH groups than in the SS group (P = 0.045 and 0.007, respectively) (Fig. 3) . The expression of acetyl-CoA carboxylase (ACC) 1 was also significantly decreased in the advanced NASH group compared with the SS group (P = 0.015), as was the expression of diacylglycerol acyltransferase (DGAT) 1 (P = 0.008) (Fig. 3) . Furthermore, the mRNA levels of these enzymes demonstrated significant inverse correlations with fibrosis stage (r = -0.427, P < 0.001 for FAS; r = -0.338, P = 0.015 for ACC1; and r = -0.367, P = 0.010 for DGAT1). On the other hand, the mRNA levels of other lipogenic enzymes, including ACC2, stearoyl-CoA desaturase 12 (SCD), and DGAT2 did not differ among the groups (Fig. 3) .
Decreased SREBP-1c mRNA Levels in Advanced NASH
Since the mRNA levels of the above lipogenic enzymes are known to be regulated by SREBP-1c [6, 20] , its expression was evaluated next. The mRNA levels of SREBP-1c were positively correlated with those of FAS (r = 0.570, P < 0.001), ACC1 (r = 0.572, P < 0.001), and DGAT1 (r = 0.516, P < 0.001). In addition to meaningful differences between the SS group and mild NASH or advanced NASH group (P = 0.049 and 0.010, respectively) ( (Fig. 4A ).
Decreased Mature SREBP-1c Levels in Advanced NASH
The activity of SREBP-1c is influenced by several post-transcriptional modification steps, i.e., processing of precursor SREBP-1c proteins (maturation) and translocation of mature SREBP-1c proteins into the nucleus [6, 20] . To confirm whether mature SREBP-1c levels were also reduced in advanced NASH, immunoblot analysis was performed. Hepatic levels of mature SREBP-1c were significantly increased in the SS group compared with normal controls (P < 0.001), but were significantly decreased in the mild and advanced NASH groups compared with the SS group (both P < 0.001) (Fig. 5) . Mature SREBP-1c levels were positively correlated with those of FAS (r = 0.403, P = 0.004), ACC1 (r = 13 0.359, P = 0.014), and DGAT1 (r = 0.355, P = 0.021), and were inversely correlated with fibrosis stage (r = -0.702, P < 0.001).
The degree of nuclear translocation of SREBP-1c was also determined by immunohistochemical analysis. Hepatocyte nuclei intensely stained with anti-SREBP-1 antibody were observed preferentially in the SS group, but were extremely rare in the advanced NASH group (black arrowheads in Fig. 6A ).
Furthermore, although hepatocytes showing cytoplasmic staining for SREBP-1c
were detected mainly in both NASH subgroups, their intensity was comparatively weaker in the advanced NASH group (black arrows in Fig. 6A) . Lastly, the number of SREBP-1c-positive hepatocyte nuclei was significantly increased in the SS group compared with normal controls (P < 0.001), but was significantly decreased in the mild and advanced NASH groups compared with the SS group (both P < 0.001) (Fig. 6B ).
Taken together, these results demonstrate that down-regulation of SREBP-1c and its downstream genes is associated with the attenuation of hepatic steatosis in advanced NASH, namely, the development of burned-out NASH.
Hepatic Expression of PPARs and RXR
The expression of PPARs, another group of transcriptional factors involved in hepatic FA/TG metabolism, were also addressed in this study. The mRNA levels of PPAR were decreased in the mild NASH and advanced NASH groups compared with the SS group (P = 0.038 and 0.007, respectively) (Fig. 4B ), and were inversely correlated with the stage of fibrosis (r = -0.432, P = 0.003).
However, immunoblot analysis revealed no significant differences in PPAR protein levels among the groups (Fig. 7) . Furthermore, the levels of PPAR 14 PPAR and a heterodimeric partner of PPARs, RXR [21] , remained unchanged in qPCR and immunoblot analyses ( Fig. 4B and 7) . Consistent with the immunoblot results were no meaningful differences in the mRNA levels of the PPAR target genes CPT1, MCAD, AOX and FABP1 [22] [23] [24] [25] , the PPAR/ target genes pyruvate dehydrogenase kinase (PDK) 4 and angiopoietin-like protein 4 (ANGPTL4) [26, 27] , or the PPAR target genes FABP4 and fat-specific protein 27 (FSP27) [28, 29] among the groups ( Fig. 2 and Supplementary Fig. 1 ).
Increased Expression of Pro-inflammatory Cytokines in Advanced NASH
The mRNA levels of SREBP-1c are reported to be down-regulated by several pro-inflammatory cytokines [30] . We observed that the expression of TNF- and its receptors, TNR1 and TNR2, was increased in parallel with fibrosis progression in NAFLD patients (r = 0.442, P = 0.008 for TNF-; r = 0.377, P = 0.033 for TNR1; and r = 0.383, P = 0.037 for TNR2) (Fig. 8) . The mRNA levels of TNF- and TNR1 were significantly higher in the advanced NASH group than those in the normal group (P = 0.041 and 0.026, respectively). The mRNA levels of interleukin (IL)-1 and its receptor (IL-1R) tended to increase with disease progression, but not significantly (Fig. 8) . There was also no statistical difference in hepatic IL-6 mRNA levels among the NAFLD subgroups ( To our knowledge, this is the first study to explore the changes in hepatic SREBP-1c expression throughout the advancement of NAFLD.
It is conceivable that the down-regulation of SREBP-1c in advanced NASH
stems from a reduction in the relative number of hepatocytes, but immunoblot analysis demonstrated a significant reduction in functional SREBP-1c levels with NAFLD progression. Furthermore, the ratio of SREBP-1c-positive hepatocyte nuclei to all hepatocyte nuclei was decreased in advanced NASH, confirming that this possibility is considered to be extremely low.
It is reported that LXR, RXR, insulin, and pro-inflammatory cytokines, such as TNF- and IL-1, can modulate the mRNA levels of SREBP-1c [20, 30] .
However, there were no significant differences in the expression of LXRRXR or serum insulin in our cohort. On the other hand, we found that hepatic mRNA levels of TNF- and its receptors increased with fibrosis progression and were inversely related to those of SREBP-1c. Such a relationship is consistent with the result in a previous study that TNF- and IL-1, 16 but not IL-6, reduced the mRNA levels of SREBP-1c in Hep3B cells [30] .
Furthermore in that in vitro experiment, the ability of TNF- to reduce SREBP-1c mRNA levels was more marked than that of IL-1 [30] . Based on these findings and our own, we can speculate that hepatic overexpression of TNF- is associated with down-regulation of SREBP-1c and the development of burned-out NASH. Adenosine monophosphate-activated protein kinase (AMPK)
is also known to be activated in response to oxidative stress and inhibit de novo lipogenesis through suppressing the transcriptional activity of SREBP-1c [6] .
Further study is necessary to investigate the contribution of AMPK activation to the pathogenesis of burned-out NASH.
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